The Medical Letter on Drugs and Therapeutics
Pomalidomide (Pomalyst) for Multiple Myeloma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved pomalidomide (Pomalyst – Celgene), an oral thalidomide analog, for treatment of patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide (Revlimid) and bortezomib (Velcade) and whose disease had progressed on or within 60 days of completion of the last therapy.

MULTIPLE MYELOMA — Use of drug regimens that include bortezomib,1 a proteasome inhibitor, plus thalidomide (Thalomid) or lenalidomide,2 another thalidomide analog, has led to improved response rates and survival in patients with multiple myeloma. Carfilzomib (Kyprolis),3 a second proteasome inhibitor, is approved for treatment of refractory multiple myeloma. Many patients do not respond to these drugs ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pomalidomide (Pomalyst) for Multiple Myeloma (online only)
Article code: 1467h
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian